X T L Biopharmaceuticals reported $371K in Cash and Equivalent for its fiscal quarter ending in December of 2024.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Bioline Rx USD 7.91M 725K Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
X T L Biopharmaceuticals USD 371K 449K Dec/2024